Holen Sie sich die Stockscreener-App
1.61
1.90%
0.03
Vorhandelsmarkt:
1.63
0.02
+1.24%
Schlusskurs vom Vortag:
$1.58
Offen:
$1.6
24-Stunden-Volumen:
1.00M
Relative Volume:
1.31
Marktkapitalisierung:
$98.93M
Einnahmen:
$5.03M
Nettoeinkommen (Verlust:
$-185.41M
KGV:
-0.521
EPS:
-3.09
Netto-Cashflow:
$-139.79M
1W Leistung:
+3.87%
1M Leistung:
-9.55%
6M Leistung:
+19.26%
1J Leistung:
-88.10%
1-Tages-Spanne:
$1.58
$1.63
1-Wochen-Bereich:
$1.53
$1.63
52-Wochen-Spanne:
$1.1001
$15.80
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Firmenname
Pliant Therapeutics Inc
Sektor
Branche
Telefon
650-481-6770
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie PLRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.61 | 97.09M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-03-04 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Herabstufung | Needham | Buy → Hold |
| 2025-03-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-02-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-04-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-07 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-20 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Cowen | Outperform |
| 2020-06-29 | Eingeleitet | Needham | Buy |
| 2020-06-29 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
What drives Pliant Therapeutics Inc stock priceCapital Gains Strategies & Access Advanced Stock Screening Tools - earlytimes.in
Wall Street analysts’ outlook for Pliant Therapeutics Inc (PLRX) - Setenews
Total debt per share of Pliant Therapeutics, Inc. – SWB:9PT - TradingView
Pliant Therapeutics, Inc. (PLRX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
What analysts say about Pliant Therapeutics Inc stockPrice Momentum Alerts & Small Capital Wealth Plans - earlytimes.in
Is Pliant Therapeutics Inc a good long term investmentFibonacci Extensions & Small Budget Trading Plans - earlytimes.in
Why Pliant Therapeutics Inc. (9PT) stock benefits from AI revolutionWeekly Loss Report & Accurate Intraday Trading Signals - newser.com
Can Pliant Therapeutics Inc. (9PT) stock double in coming yearsGold Moves & Safe Capital Allocation Plans - newser.com
Why Pliant Therapeutics Inc. stock is in analyst buy zone2025 Price Targets & Low Drawdown Investment Strategies - newser.com
How rising interest rates impact Pliant Therapeutics Inc. stockJuly 2025 Weekly Recap & Fast Entry High Yield Stock Tips - newser.com
Pliant Therapeutics Inc (PLRX) expanding its growth trajectory ahead - Setenews
Why global investors buy Pliant Therapeutics Inc. (9PT) stock2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - newser.com
What high frequency data says about Pliant Therapeutics Inc.July 2025 News Drivers & Risk Adjusted Buy/Sell Alerts - newser.com
Why Pliant Therapeutics Inc. (9PT) stock could be top winnerMarket Performance Report & Free Real-Time Volume Trigger Notifications - newser.com
Does Pliant Therapeutics Inc. show high probability of reboundMarket Performance Report & Free Accurate Trade Setup Notifications - newser.com
Is Pliant Therapeutics Inc. stock near bottom after decline2025 Stock Rankings & Community Consensus Stock Picks - newser.com
Can Pliant Therapeutics Inc. stock maintain operating margins2025 Year in Review & Real-Time Stock Price Movement Reports - newser.com
Heatmap analysis for Pliant Therapeutics Inc. and competitors2025 Volume Leaders & Community Verified Watchlist Alerts - newser.com
Chart overlay techniques for tracking Pliant Therapeutics Inc.Weekly Trend Recap & Real-Time Stock Entry Alerts - newser.com
Is Pliant Therapeutics Inc. stock a safe buy before earningsWeekly Trading Summary & Expert Approved Trade Ideas - Fundação Cultural do Pará
How analysts rate Pliant Therapeutics Inc. stock todayTrade Risk Summary & AI Powered Buy and Sell Recommendations - Fundação Cultural do Pará
Will Pliant Therapeutics Inc. stock deliver shareholder valueQuarterly Portfolio Report & AI Based Trade Execution Alerts - Fundação Cultural do Pará
Why Pliant Therapeutics Inc. stock is popular among millennialsLayoff News & High Return Stock Watch Alerts - Fundação Cultural do Pará
Are Smart Investors Making the Right Decision? Pliant Therapeutics Inc (PLRX) - Setenews
Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):